6 Biotech Stocks In Focus: Modular Medical, Galmed, Pro-Dex, Connect Biopharma & More
Modular Medical (MODD) received FDA clearance for software enhancements to its Pivot insulin pump, planning a commercial launch in October 2026. Galmed (GLMD) shareholders approved all proposals, including a name change. Pro-Dex (PDEX) reported strong Q4 results with 17% sales growth. eHealth (EHTH) saw after-hours gains despite a Q2 net loss. Connect Biopharma (CNTB) will present at a conference and report Phase 2 trial results. AVITA Medical (RCEL) expects full-year revenue of $86M-$89M.
How this was made
The 30-second read
Why it matters
The combined news provides several short‑term catalysts, especially for MODD, GLMD, and PDEX, while other names have more speculative or longer‑term drivers.
Market read
Multiple micro‑cap health‑care stocks received fresh catalysts, creating short‑term trading opportunities.
What to watch
Potential reimbursement challenges and competitive pressure in insulin delivery market.
Background
A roundup of recent after‑hours movers in the biotech and med‑tech space, featuring FDA clearance, AGM approvals, earnings, and upcoming trial data.
Ticker impact
FDA cleared software enhancements for Modular Medical's Pivot tubeless insulin patch pump.
Short-term upside as after‑hours price rose 5.6%; could sustain if launch proceeds.
Regulatory approval is a material catalyst for a commercial‑stage device company.
Shareholders approved all five proposals at Galmed's AGM, including a name change to Eocene Ltd.
Modest upside; after‑hours price jumped 9.7% on the news.
AGM approvals are routine but the name change signals strategic shift.
Pro‑Dex reported Q4 FY2026 results with 17% sales growth and earnings jump to $0.87 EPS.
Shares rose >9% after hours; likely to stay elevated if guidance holds.
Quarterly earnings beat and margin expansion are clear catalysts.
eHealth shares rose >8% after hours despite no specific news, following a recent loss report.
Potential short‑term volatility; no clear directional bias.
No new corporate event; price move appears momentum‑driven.
Connect Biopharma announced management will speak at a conference and expects Phase‑2 results this month.
After‑hours price up 3%; could rise further on trial readouts.
Phase‑2 data releases are material for clinical‑stage biotech.
AVITA Medical (RCEL) scheduled for two investor conferences and reported Q2 revenue growth.
Shares modestly higher; limited immediate impact.
Conference announcements are routine and not a strong catalyst.
Market effects
Highlights ongoing innovation and regulatory progress in the medical‑device and biotech sectors.
U.S. biotech and med‑tech stocks may see modest uplift.
Limited to investors focused on U.S. listed health‑care companies.
Counterpoint
Regulatory approvals may not translate into commercial success; execution risk remains high.
Key entities
- CompanyModular Medical Inc.
Medical‑device firm with FDA‑cleared insulin patch pump enhancements.
- CompanyGalmed Pharmaceuticals Ltd.
Pharma company that approved AGM proposals and a name change.
- CompanyPro‑Dex Inc.
Surgical device maker reporting strong Q4 earnings.
- CompanyeHealth Inc.
Health‑insurance marketplace with recent loss report.
- CompanyConnect Biopharma Holdings Limited
Biotech firm expecting Phase‑2 trial readouts.
